Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505.
Griswold
D E
DE
Smith Kline and French Laboratories, Department of Immunology, King of Prussia, PA 19406.
Egan
J W
JW
Earl
C Q
CQ
Hillegass
L M
LM
Marshall
P J
PJ
Smith
E F
EF
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D000818:Animals; D003327:Coronary Disease / Q000188:drug therapy / Q000473:pathology; D008297:Male; D009203:Myocardial Infarction / Q000473:pathology / Q000517:prevention & control; D015428:Myocardial Reperfusion Injury / Q000473:pathology / Q000517:prevention & control*; D009504:Neutrophils / Q000187:drug effects / Q000473:pathology; D010648:Phenylacetates / Q000494:pharmacology*; D011450:Prostaglandin Endoperoxides, Synthetic / Q000037:antagonists & inhibitors; D051381:Rats; D011919:Rats, Inbred Strains; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D013449:Sulfonamides / Q000494:pharmacology*
D010648:Phenylacetates; D011450:Prostaglandin Endoperoxides, Synthetic; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D013449:Sulfonamides; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; C051762:daltroban